Cargando…

Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema

Psoriasis is a chronic inflammatory disease which mostly affects skin. Tildrakizumab is a specific anti-interleukin -23p19 monoclonal antibody approved for the treatment of plaque psoriasis in adults. Herein, we report about a patient who came to our attention for a moderate-to-severe plaque psorias...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bernardini, Nicoletta, Skroza, Nevena, Rossi, Giovanni, Mambrin, Alessandra, Tolino, Ersilia, Marraffa, Federica, Caviglia, Martina, Guardo, Antonio Di, Volpe, Salvatore, Proietti, Ilaria, Potenza, Concetta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications, Pavia, Italy 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724640/ https://www.ncbi.nlm.nih.gov/pubmed/36483227 http://dx.doi.org/10.4081/dr.2022.9447

Ejemplares similares

A case of twins affected by psoriasis, psoriatic arthritis and autism: Five years of efficacious and safe treatment with Secukinumab
por: Bernardini, Nicoletta, et al.
Publicado: (2022)

Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient
por: Bernardini, Nicoletta, et al.
Publicado: (2022)

Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience
por: Skroza, Nevena, et al.
Publicado: (2021)

Aesthetic Treatments in Cancer Patients
por: Proietti, Ilaria, et al.
Publicado: (2021)

Advantages of Tailored Isotretinoin Treatment in Moderate to Severe Acne: Real-Life Data
por: Skroza, Nevena, et al.
Publicado: (2021)

Long-Term Maintained Response to Selective Internal Radiation Therapy in an Oligometastatic Uveal Melanoma Patient Treated with Concomitant Anti-PD-1 Therapy
por: Proietti, Ilaria, et al.
Publicado: (2021)

A Case of Psoriatic Disease and Hidradenitis Suppurativa in a Child with Chromosome 17q21.31 Microduplication Syndrome
por: Tolino, Ersilia, et al.
Publicado: (2023)

Efficacy of Cemiplimab in a Patient Affected by Cutaneous Squamous Cell Carcinoma and Myelodysplastic Syndrome
por: Proietti, Ilaria, et al.
Publicado: (2023)

A Review of the Literature of Surgical and Nonsurgical Treatments of Invasive Squamous Cells Carcinoma
por: Potenza, Concetta, et al.
Publicado: (2018)

Do Diet and Lifestyles Play a Role in the Pathogenesis of NMSCs?
por: Skroza, Nevena, et al.
Publicado: (2020)

Correlations between Psoriasis and Inflammatory Bowel Diseases
por: Skroza, Nevena, et al.
Publicado: (2013)

Adverse skin reactions to personal protective equipment during COVID‐19 pandemic in Italian health care workers
por: Proietti, Ilaria, et al.
Publicado: (2022)

Factors influencing response to ingenol mebutate therapy for actinic keratosis of face and scalp
por: Skroza, Nevena, et al.
Publicado: (2017)

The Role of the Western Diet on Atopic Dermatitis: Our Experience and Review of the Current Literature
por: Ilaria, Proietti, et al.
Publicado: (2023)

Evaluation of Cardiovascular Risk in Hidradenitis Suppurativa Patients Using Heart Rate Variability (HRV) Analysis
por: Skroza, Nevena, et al.
Publicado: (2020)

IL‐17 and its role in inflammatory, autoimmune, and oncological skin diseases: state of art
por: Bernardini, Nicoletta, et al.
Publicado: (2019)

Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review
por: Proietti, Ilaria, et al.
Publicado: (2020)

BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions
por: Proietti, Ilaria, et al.
Publicado: (2020)

Eruptive Blue Nevi of the Scalp in a Patient with Mayer–Rokitansky–Küster–Hauser Syndrome during Isotretinoin Therapy
por: Skroza, Nevena, et al.
Publicado: (2019)

Clinical utility of ingenol mebutate in the management of actinic keratosis: perspectives from clinical practice
por: Skroza, Nevena, et al.
Publicado: (2018)

Management of psoriatic patients in biologic treatment associated with infectious comorbidities
por: Nicoletta, Bernardini, et al.
Publicado: (2020)

Cardiovascular risk evaluation through heart rate variability analysis in psoriatic patients before and after 24 weeks of etanercept therapy: Prospective study
por: Potenza, Concetta, et al.
Publicado: (2016)

Supraorbital Basosquamous Carcinoma Treated with Cemiplimab Followed by Sonidegib: A Case Report and Review of the Literature
por: Proietti, Ilaria, et al.
Publicado: (2023)

A Case Report of Monkeypox in an Adult Patient from Italy: Clinical and Dermoscopic Manifestations, Diagnosis and Management
por: Proietti, Ilaria, et al.
Publicado: (2022)

Tildrakizumab in moderate‐to‐severe plaque psoriasis: A multicenter, retrospective, real‐life study
por: Caldarola, Giacomo, et al.
Publicado: (2022)

How lockdown measures, during COVID-19 pandemic, matter on psoriatic patient’s perception: Study on 600 patients on biologic therapy
por: Bernardini, N., et al.
Publicado: (2021)

Erythrodermic psoriasis improved by Tildrakizumab
por: Trevisan, Giampaolo, et al.
Publicado: (2022)

Tildrakizumab in the treatment of psoriasis – literature review
por: Banaszczyk, Katarzyna
Publicado: (2019)

Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy
por: Pithadia, Deeti J., et al.
Publicado: (2019)

Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?
por: Megna, Matteo, et al.
Publicado: (2021)

Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
por: Burlando, Martina, et al.
Publicado: (2021)

A Case of Concurrent Psoriasis and Hidradenitis Suppurativa Successfully Treated with Tildrakizumab
por: Damsin, Thomas
Publicado: (2023)

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
por: Beck, Kristen M, et al.
Publicado: (2018)

Erratum: Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
Publicado: (2021)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Incidence of serious gastrointestinal events among tildrakizumab‐treated patients with psoriasis: Letter to the Editor
por: Gooderham, M., et al.
Publicado: (2019)

Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis
por: Galluzzo, Marco, et al.
Publicado: (2022)

The Dermatological Effects and Occupational Impacts of Personal Protective Equipment on a Large Sample of Healthcare Workers During the COVID-19 Pandemic
por: Santoro, Paolo Emilio, et al.
Publicado: (2022)

Nature of Eczema and Psoriasis
Publicado: (1878)

Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
por: Näslund-Koch, Charlotte, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_326vfi1jfq3rgc477ue4ra47ie